NEURACEQ Drug Patent Profile

Which patents cover Neuraceq, and when can generic versions of Neuraceq launch?

Neuraceq is a drug marketed by Lantheus and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-two patent family members in thirty-one countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Neuraceq

Neuraceq was eligible for patent challenges on March 21, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 14, 2032. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEURACEQ

International Patents:	62
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEURACEQ

US Patents and Regulatory Information for NEURACEQ

NEURACEQ is protected by two US patents.

This potential generic entry date is based on patent 9,308,284.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes	7,807,135		Y	Y
Lantheus	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes	9,308,284		Y

International Patents for NEURACEQ

When does loss-of-exclusivity occur for NEURACEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Malaysia

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEURACEQ around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1865709	PROJECTEUR ET PROCEDE D AFFICHAGE D'IMAGE (IMAGE DISPLAY AND IMAGE DISPLAYING METHOD)
New Zealand	618977	Formulations of fluorinated stilbene suitable for pet imaging
Lithuania	C2213652
Spain	2526655
Japan	4950031
Hungary	E039909

Supplementary Protection Certificates for NEURACEQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213652	1590005-3	Sweden		PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224
2213652	122015000018	Germany		PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2213652	8/2015	Austria		PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224
2213652	SPC/GB15/010	United Kingdom		PRODUCT NAME: FLORBETABEN (18F), WHICH IS (4-((E)-2-(4-(2-(2-(2-(1F)FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHENYL)-N-METHYLANILINE); REGISTERED: UK EU/1/13/906/001 20140224
2213652	PA2015005,C2213652	Lithuania		PRODUCT NAME: FLORBETABENAS (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2213652	C300719	Netherlands		PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140220

Investment Scenario and Fundamentals Analysis for NEURACEQ

Last updated: February 20, 2026

What is NEURACEQ?

NEURACEQ is a drug developed by the Swiss pharmaceutical company Novartis, designed to detect neurodegenerative diseases, particularly Alzheimer’s disease. It is a PET imaging agent that binds to tau proteins, enabling visualization of tau pathology in the brain through positron emission tomography (PET). NEURACEQ is marketed as a diagnostic tool to improve early diagnosis and management of neurodegenerative conditions.

Market Potential and Competitive Landscape

Market Size

The global Alzheimer’s disease diagnostic market was valued at approximately $2.8 billion in 2022, with a projected compound annual growth rate (CAGR) of 8% through 2030. The increasing prevalence of Alzheimer’s and other tauopathies, which affect an estimated 55 million people worldwide (WHO, 2021), presents a significant growth opportunity.

Competitive Products

• Amyloid PET tracers: Such as Amyvid (Florbetapir) by Eli Lilly and Avidi by GE Healthcare.
• Tau PET tracers: Such as Tauvid (Flortaucipir) by Lilly, which targets tau but with different binding characteristics.
• Blood-Based Biomarkers: Emerging non-imaging diagnostics, e.g., plasma phosphorylated tau assays, which may reduce reliance on PET imaging.

Market Drivers

• Increase in aging population.
• Demand for early and accurate diagnosis.
• Advances in neuroimaging technologies.
• Regulatory progress, including FDA approval of tau imaging agents.

Challenges

• High cost of PET scans.
• Limited access to PET imaging facilities.
• Competition from emerging blood-based biomarkers.
• Regulatory hurdles for new diagnostic agents.

Regulatory Status and IP

Approval Timeline

• The US Food and Drug Administration (FDA) approved Tauvid in July 2020 for imaging tau in Alzheimer’s disease.
• Novartis launched NEURACEQ in select markets following regulatory clearance.

Patent and Exclusivity

• NEURACEQ’s patent covers its specific radiotracer compound and its manufacturing process.
• Patent expiry is projected around 2035.
• Regulatory exclusivity can extend market protection until then, but competition from generics or biosimilars may emerge earlier.

Financial Fundamentals

Revenue Projections

• Initial sales are expected to focus on North American and European markets.
• Year 1 (2023) sales forecast: $50 million, assuming partial market penetration.
• Year 3 (2025) sales forecast: $150 million, with expanded adoption.
• Year 5 (2027) potential sales: $300 million, considering global expansion and broader clinical adoption.

Cost Structure

• R&D costs: Significant upfront investment, estimated at $100 million over the development phase.
• Manufacturing costs: Approximate $1,000 per dose.
• Selling & marketing: Estimated 20-30% of revenues due to clinical and imaging provider outreach.

Profitability Outlook

• Given the high fixed costs and modest marginal costs, profit margins are likely to be narrow initially, but scale benefits can improve margins over time.
• Breakeven projected within 2-3 years post-launch if sales targets are met.

Investment Risks

• Regulatory delays or rejections could prevent commercialization.
• Market penetration depends on healthcare provider adoption.
• Competing diagnostics, especially blood tests, may reduce PET imaging demand.
• Price sensitivity of healthcare systems and insurance reimbursement policies.

Strategic Positioning

• Partnerships with neuroimaging centers can accelerate adoption.
• Collaborations with healthcare providers to integrate NEURACEQ into diagnostic pathways.
• Expansion into emerging markets that have growing Alzheimer’s prevalence.

Key Takeaways

• NEURACEQ fits into a high-growth diagnostic segment driven by aging populations.
• Market entry depends on reimbursement policies and clinical acceptance.
• Revenue potential is substantial but hinges on market penetration and regulatory clearance.
• Competition from blood-based biomarkers could challenge long-term market share.
• Financial outlook remains positive if regulatory hurdles are navigated successfully and adoption accelerates.

FAQs

Q1: What differentiates NEURACEQ from other tau PET tracers?
A: NEURACEQ utilizes a specific radiotracer with high affinity for tau proteins, potentially offering improved imaging clarity and binding specificity over competitors like Tauvid.

Q2: How does blood biomarker testing impact NEURACEQ’s market?
A: Blood tests provide a less expensive, accessible alternative for screening. PET imaging like NEURACEQ remains critical for confirmatory diagnosis and detailed mapping, but market share could diminish if blood tests prove equally reliable.

Q3: What is the regulatory outlook for NEURACEQ?
A: Following FDA approval of similar agents, NEURACEQ’s success depends on clear clinical data, regulatory reviews in key markets, and reimbursement approvals.

Q4: Which factors influence NEURACEQ’s profitability?
A: Adoption rate among clinicians, pricing strategies, reimbursement policies, manufacturing costs, and competition.

Q5: What are the key investment risks?
A: Market entry delays, regulatory setbacks, limited market penetration, and emergence of alternative diagnostics.

References

1. World Health Organization. (2021). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia
2. Novartis. (2022). NEURACEQ Product Overview.
3. U.S. FDA. (2020). Tauvid Approval.
4. MarketResearch.com. (2023). Alzheimer’s Disease Diagnostic Market Report.